Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2016-06-22 Investor Presentation
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
NTCELL Trial Results to be Presented in Berlin 4 pages 838.9KB
Investor Presentation Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited regarding the presentation of clinical trial results for their NTCELL therapy for Parkinson's disease. It includes detailed clinical trial data, safety and efficacy results, and information about the therapy and company. The document is about the presentation of trial results at a conference, not a full financial or regulatory report. It is not a transcript of a call, nor a management or earnings report. It is a public announcement of clinical trial results and related information, typical of an investor or market announcement. Given the content and context, the best fitting category is Investor Presentation (IP), as it focuses on clinical trial results, product information, and company strategy for investors and the market. The document length (15,000 characters) and detailed data support this classification rather than a brief announcement or regulatory filing.
2016-06-22 English
Response to ASX Price Query 4 pages 259.3KB
Regulatory Filings Classification · 95% confidence The document is a letter from the Australian Securities Exchange (ASX) to Living Cell Technologies Limited regarding a price query about recent trading activity in the company's securities. The letter requests the company to respond to questions about any undisclosed information that might explain the price movement and confirms compliance with ASX Listing Rules. The company's response is included, stating no undisclosed information exists and referencing a prior announcement and upcoming conference presentation. The document is a regulatory compliance communication related to market disclosure obligations, not a financial report, earnings release, or other specific report type. It is also not a report publication announcement since it contains substantive responses to ASX queries. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2016-06-21 English
Appendix 3B 9 pages 322.3KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to securities issuance and quotation. It details the issuance of unquoted options, exercise price, vesting, expiry, number of securities issued, and application for quotation of additional securities. The content is regulatory in nature, focused on announcing a new securities issue and applying for their quotation on the ASX. It does not contain financial statements, management discussion, or audit information. It is not a report but an official announcement form used for capital raising and securities issuance disclosures. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance information, supporting a high confidence classification.
2016-06-07 English
NTCELL demonstrates continued reversal of Parkinsons 4 pages 387.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 7 June 2016. It reports clinical study results for their product NTCELL® related to Parkinson's disease, including data on patient outcomes and future study plans. The content is focused on clinical trial progress and product development updates rather than financial results, management changes, or regulatory filings. It does not contain financial statements or detailed financial analysis, nor does it announce voting results, dividends, or capital changes. The document is a corporate announcement about clinical trial progress and product development, which fits best under the category of a general regulatory announcement or compliance update. Given the absence of financial data or formal report content, the most appropriate classification is Regulatory Filings (RNS). The document length (over 10,000 characters) and detailed content support that it is not a mere report publication announcement but a substantive announcement. Confidence is high due to clear content focus and format.
2016-06-06 English
Appendix 4G 12 pages 537.5KB
Governance Information Classification · 95% confidence The document is an ASX Announcement titled 'Appendix 4G' lodged by Living Cell Technologies Limited. It references compliance with ASX Listing Rules 4.7.3 and 4.10.3, which require lodging a corporate governance statement either within the annual report or separately. The document states that the corporate governance statement is available on the company's website and that the Appendix 4G is lodged in connection with the 2015 Annual Financial Statements. The content primarily details corporate governance disclosures and compliance with governance recommendations, not the full annual report or financial statements themselves. The document is about governance disclosures and compliance, not the full annual report or financial data. It is not a full Annual Report (10-K), nor an Interim Report, nor an Earnings Release. It is not a report publication announcement since it contains substantive governance disclosure content. The document fits best under Governance Information (CGR) as it details the company's governance practices and compliance with ASX Corporate Governance Council Principles and Recommendations.
2016-05-15 English
Appendix 3B 9 pages 343.3KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and references specific ASX rules (2.7, 3.10.3, 3.10.4, 3.10.5) related to securities issuance and quotation. It details the issuance of unquoted options, number of securities, terms, issue price, purpose, and quotation application. The content is regulatory in nature, focused on announcing a new securities issue and applying for quotation on the ASX. It does not contain financial statements, management discussion, or earnings data. It is a formal announcement of a capital raising event and securities issuance, consistent with a Capital/Financing Update filing. The document length is substantial and contains detailed information about the securities issued, but it is not a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-05-09 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.